Sense-antisense gene-pairs in breast cancer and associated pathological pathways

More than 30% of human protein-coding genes form hereditary complex genome architectures composed of sense-antisense (SA) gene pairs (SAGPs) transcribing their RNAs from both strands of a given locus. Such architectures represent important novel components of genome complexity contributing to gene expression deregulation in cancer cells. Therefore, the architectures might be involved in cancer pathways and, in turn, be used for novel drug targets discovery. However, the global roles of SAGPs in cancer pathways has not been studied. Here we investigated SAGPs associated with breast cancer (BC)-related pathways using systems biology, prognostic survival and experimental methods. Gene expression analysis identified 73 BC-relevant SAGPs that are highly correlated in BC. Survival modelling and metadata analysis of the 1161 BC patients allowed us to develop a novel patient prognostic grouping method selecting the 12 survival-significant SAGPs. The qRT-PCR-validated 12-SAGP prognostic signature reproducibly stratified BC patients into low- and high-risk prognostic subgroups. The 1381 SAGP-defined differentially expressed genes common across three studied cohorts were identified. The functional enrichment analysis of these genes revealed the GABPA gene network, including BC-relevant SAGPs, specific gene sets involved in cell cycle, spliceosomal and proteasomal pathways. The co-regulatory function of GABPA in BC cells was supported using siRNA knockdown studies. Thus, we demonstrated SAGPs as the synergistically functional genome architectures interconnected with cancer-related pathways and associated with BC patient clinical outcomes. Taken together, SAGPs represent an important component of genome complexity which can be used to identify novel aspects of coordinated pathological gene networks in cancers.

[1]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[2]  J. Kutok,et al.  BAL1 and BBAP Are Regulated by a Gamma Interferon-Responsive Bidirectional Promoter and Are Overexpressed in Diffuse Large B-Cell Lymphomas with a Prominent Inflammatory Infiltrate , 2006, Molecular and Cellular Biology.

[3]  Sunghoon Kim,et al.  Lentiviral vector-mediated shRNA against AIMP2-DX2 suppresses lung cancer cell growth through blocking glucose uptake , 2012, Molecules and cells.

[4]  Joshy George,et al.  Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. , 2006, Cancer research.

[5]  Minoru Yoshida,et al.  Splicing in oncogenesis and tumor suppression , 2012, Cancer science.

[6]  Yuan Yuan,et al.  Inhibition of breast and brain cancer cell growth by BCCIPα, an evolutionarily conserved nuclear protein that interacts with BRCA2 , 2001, Oncogene.

[7]  W. Cai,et al.  Comparative RNA-seq analysis reveals potential mechanisms mediating the conversion to androgen independence in an LNCaP progression cell model. , 2014, Cancer letters.

[8]  T. Yokota,et al.  GABPalpha regulates Oct-3/4 expression in mouse embryonic stem cells. , 2007, Biochemical and biophysical research communications.

[9]  G. Nahler disease free survival (DFS) , 2009 .

[10]  Vladimir A Kuznetsov,et al.  In the pursuit of complexity: systems medicine in cancer biology. , 2006, Cancer cell.

[11]  Barnett,et al.  Supplementary References , 2022 .

[12]  Shridar Ganesan,et al.  X chromosomal abnormalities in basal-like human breast cancer. , 2006, Cancer cell.

[13]  L. Holmberg,et al.  Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts , 2005, Breast Cancer Research.

[14]  Jie Xu,et al.  Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells , 2012, Autophagy.

[15]  Y. Assaraf,et al.  Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance , 2015, Expert opinion on drug metabolism & toxicology.

[16]  R. Medema,et al.  Aurora-A and hBora join the game of Polo. , 2009, Cancer research.

[17]  Mårten Fryknäs,et al.  Inhibition of proteasome deubiquitinating activity as a new cancer therapy , 2011, Nature Medicine.

[18]  D. Hoyle,et al.  Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection , 2009, Genome Biology.

[19]  N. Kohno,et al.  Functional evidence for Eme1 as a marker of cisplatin resistance , 2009, International journal of cancer.

[20]  Vladimir A Kuznetsov,et al.  Meta‐analysis of transcriptome reveals let‐7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high‐grade serous ovarian carcinoma , 2014, International journal of cancer.

[21]  M. Marra,et al.  Extensive relationship between antisense transcription and alternative splicing in the human genome. , 2011, Genome research.

[22]  V. Kuznetsov,et al.  Data-driven approach to predict survival of cancer patients: estimation of microarray genes' prediction significance by Cox proportional hazard regression model. , 2009, IEEE engineering in medicine and biology magazine : the quarterly magazine of the Engineering in Medicine & Biology Society.

[23]  J. Cadiñanos,et al.  Novel germline SDHD deletion associated with an unusual sympathetic head and neck paraganglioma , 2011, Head & neck.

[24]  S. Scherer,et al.  Subgroup-specific alternative splicing in medulloblastoma , 2012, Acta Neuropathologica.

[25]  H. Dressman,et al.  Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. , 2008, JAMA.

[26]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[27]  Charlotta Lindvall,et al.  Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation. , 2008, Neoplasia.

[28]  B. Teh,et al.  DOK4/IRS‐5 expression is altered in clear cell renal cell carcinoma , 2007, International journal of cancer.

[29]  M. Kitagawa,et al.  Cell cycle-dependent regulation of the Skp2 promoter by GA-binding protein. , 2003, Cancer research.

[30]  Raja Jothi,et al.  GABP controls a critical transcription regulatory module that is essential for maintenance and differentiation of hematopoietic stem/progenitor cells. , 2011, Blood.

[31]  L. Giudice,et al.  Perivascular Human Endometrial Mesenchymal Stem Cells Express Pathways Relevant to Self-Renewal, Lineage Specification, and Functional Phenotype1 , 2012, Biology of reproduction.

[32]  K. Sträßer,et al.  Splicing and beyond: the many faces of the Prp19 complex. , 2013, Biochimica et biophysica acta.

[33]  A. Frigessi,et al.  Principles and methods of integrative genomic analyses in cancer , 2014, Nature Reviews Cancer.

[34]  Paloma H. Giangrande,et al.  Current progress on aptamer-targeted oligonucleotide therapeutics. , 2013, Therapeutic delivery.

[35]  Lin Ji,et al.  Tumor suppressor 101F6 and ascorbate synergistically and selectively inhibit non-small cell lung cancer growth by caspase-independent apoptosis and autophagy. , 2007, Cancer research.

[36]  Victoria Kristina Perry,et al.  Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients , 2007, International journal of cancer.

[37]  L. Steinmetz,et al.  Gene regulation by antisense transcription , 2013, Nature Reviews Genetics.

[38]  Jeffrey T. Leek,et al.  Gene expression EDGE : extraction and analysis of differential gene expression , 2006 .

[39]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[40]  M. Moore,et al.  The Biflavonoid Isoginkgetin Is a General Inhibitor of Pre-mRNA Splicing , 2008, Journal of Biological Chemistry.

[41]  S. Mott,et al.  The Ets transcription factor GABP is required for cell-cycle progression , 2007, Nature Cell Biology.

[42]  S. Michiels,et al.  Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. , 2009, The Lancet. Oncology.

[43]  Graziano Pesole,et al.  Pscan: finding over-represented transcription factor binding site motifs in sequences from co-regulated or co-expressed genes , 2009, Nucleic Acids Res..

[44]  O. Khorkova,et al.  Natural antisense transcripts as therapeutic targets. , 2013, Drug discovery today. Therapeutic strategies.

[45]  M. Moore,et al.  Meayamycin inhibits pre–messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells , 2009, Molecular Cancer Therapeutics.

[46]  H. P. Kang,et al.  Cancer-Associated Splicing Variant of Tumor Suppressor AIMP2/p38: Pathological Implication in Tumorigenesis , 2011, PLoS genetics.

[47]  C. Will,et al.  The Spliceosome: Design Principles of a Dynamic RNP Machine , 2009, Cell.

[48]  神代 理史 The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways , 2009 .

[49]  A. Chalk,et al.  RNAi Screen Indicates Widespread Biological Function for Human Natural Antisense Transcripts , 2010, PloS one.

[50]  Mieke Timmermans,et al.  Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  J. Pietenpol,et al.  Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes , 2014, The Journal of pathology.

[52]  M Endo,et al.  Isolation of murine and human homologues of the fission-yeast dis3+ gene encoding a mitotic-control protein and its overexpression in cancer cells with progressive phenotype. , 1997, Cancer research.

[53]  J. Bergh,et al.  Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Krishna R. Kalari,et al.  Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. , 2010, Genome research.

[55]  W. Shoji,et al.  NCYM promotes calpain-mediated Myc-nick production in human MYCN-amplified neuroblastoma cells. , 2015, Biochemical and biophysical research communications.

[56]  David Haussler,et al.  The UCSC Genome Browser database: 2014 update , 2013, Nucleic Acids Res..

[57]  M. Piccart,et al.  Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study , 2008, British Journal of Cancer.

[58]  A. Gutierrez-Hartmann,et al.  Molecular mechanisms of ETS transcription factor-mediated tumorigenesis , 2013, Critical reviews in biochemistry and molecular biology.

[59]  Yanqing Ding,et al.  Protein and mRNA Characterization in Human Colorectal Carcinoma Cell Lines with Different Metastatic Potentials , 2007, Cancer investigation.

[60]  Xing-Hua Liao,et al.  Estrogen receptor α mediates proliferation of breast cancer MCF–7 cells via a p21/PCNA/E2F1‐dependent pathway , 2014, The FEBS journal.

[61]  J. Smyth,et al.  Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. , 2005, Cancer research.

[62]  Beatriz Carvalho,et al.  Gene‐dosage dependent overexpression at the 13q amplicon identifies DIS3 as candidate oncogene in colorectal cancer progression , 2014, Genes, chromosomes & cancer.

[63]  T. Livache,et al.  TOX4 and its binding partners recognize DNA adducts generated by platinum anticancer drugs. , 2011, Archives of biochemistry and biophysics.

[64]  L. Pasqualucci,et al.  Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. , 2011, Blood.

[65]  A. Syvänen,et al.  Digital gene expression profiling of primary acute lymphoblastic leukemia cells , 2011, Leukemia.

[66]  Jian Liu,et al.  Niemann-Pick C1 Protein Facilitates the Efflux of the Anticancer Drug Daunorubicin from Cells According to a Novel Vesicle-Mediated Pathway , 2006, Journal of Pharmacology and Experimental Therapeutics.

[67]  J. Fondell,et al.  Regulation of Aurora-A Kinase Gene Expression via GABP Recruitment of TRAP220/MED1* , 2006, Journal of Biological Chemistry.

[68]  N. Czaicki,et al.  Total syntheses, fragmentation studies, and antitumor/antiproliferative activities of FR901464 and its low picomolar analogue. , 2007, Journal of the American Chemical Society.

[69]  J. Schellens,et al.  Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. , 2011, Lung cancer.

[70]  F. André,et al.  Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy. , 2013, Cancer research.

[71]  D. Watson,et al.  CaSm antisense gene therapy: a novel approach for the treatment of pancreatic cancer. , 2003, Anticancer research.

[72]  D. Berdnik,et al.  Mitotic activation of the kinase Aurora-A requires its binding partner Bora. , 2006, Developmental cell.

[73]  Gianluca Bontempi,et al.  Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen , 2008, BMC Genomics.

[74]  Sang Kyun Sohn,et al.  MGMT −535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy , 2010, Journal of Cancer Research and Clinical Oncology.

[75]  P. Sebastiani,et al.  Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile , 2010, British Journal of Cancer.

[76]  J. Burnett,et al.  RNA-based therapeutics: current progress and future prospects. , 2012, Chemistry & biology.

[77]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[78]  S. Dhanasekaran,et al.  The landscape of antisense gene expression in human cancers , 2015, Genome research.

[79]  Masaru Tomita,et al.  Comparative expression analysis uncovers novel features of endogenous antisense transcription. , 2008, Human molecular genetics.

[80]  Clifford A. Meyer,et al.  Gene expression profiling of human breast tissue samples using SAGE-Seq. , 2010, Genome research.

[81]  Zoltan Szallasi,et al.  Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer , 2010, Nature Medicine.

[82]  H. Ditzel,et al.  Identification of markers associated with highly aggressive metastatic phenotypes using quantitative comparative proteomics. , 2012, Cancer genomics & proteomics.

[83]  Lars Juhl Jensen,et al.  Cyclebase 3.0: a multi-organism database on cell-cycle regulation and phenotypes , 2014, Nucleic Acids Res..

[84]  Thomas D. Wu,et al.  Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes , 2009, Molecular Cancer Research.

[85]  H. Kayed,et al.  Expression of MAC30 protein is related to survival and biological variables in primary and metastatic colorectal cancers. , 2007, International journal of oncology.

[86]  A. Weissman,et al.  RING-dependent tumor suppression and G2/M arrest induced by the TRC8 hereditary kidney cancer gene , 2007, Oncogene.

[87]  A. Protopopov,et al.  Altered antisense-to-sense transcript ratios in breast cancer , 2010, Proceedings of the National Academy of Sciences.

[88]  F. Montorsi,et al.  Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer , 2014, Oncogene.

[89]  Yitzhak Pilpel,et al.  Genome‐wide natural antisense transcription: coupling its regulation to its different regulatory mechanisms , 2006, EMBO reports.

[90]  R. Myers,et al.  The ets-Related Transcription Factor GABP Directs Bidirectional Transcription , 2007, PLoS genetics.

[91]  H. Tsukamura,et al.  Single-stranded Noncoding RNAs Mediate Local Epigenetic Alterations at Gene Promoters in Rat Cell Lines* , 2011, The Journal of Biological Chemistry.

[92]  Vladimir A. Kuznetsov,et al.  Statistically Weighted Voting Analysis of Microarrays for Molecular Pattern Selection and Discovery Cancer Genotypes , 2006 .

[93]  P. V. van Dam,et al.  A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  C. Wahlestedt Natural antisense and noncoding RNA transcripts as potential drug targets. , 2006, Drug discovery today.

[95]  D. Kang,et al.  Genome-wide association study of childhood acute lymphoblastic leukemia in Korea. , 2010, Leukemia research.

[96]  L. Greller,et al.  Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs , 2008, Clinical Cancer Research.

[97]  R. Roden,et al.  Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells , 2015, Oncotarget.

[98]  G. Finocchiaro,et al.  Localizing hotspots of antisense transcription , 2007, Nucleic acids research.

[99]  Vladimir A. Kuznetsov,et al.  Integrative analysis of the human cis-antisense gene pairs, miRNAs and their transcription regulation patterns , 2009, Nucleic acids research.

[100]  T. Gingeras,et al.  Genome-wide transcription and the implications for genomic organization , 2007, Nature Reviews Genetics.

[101]  C. Méndez-Vidal,et al.  Wrap53, a Natural p53 Antisense Transcript Required for p53 Induction upon DNA Damage. , 2016, Molecular cell.

[102]  V. Devanarayan,et al.  Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cells. , 2003, The American journal of pathology.

[103]  Y. Xiong,et al.  Vpr-Binding Protein Antagonizes p53-Mediated Transcription via Direct Interaction with H3 Tail , 2011, Molecular and Cellular Biology.

[104]  Raja Jothi,et al.  Critical Requirement of GABPα for Normal T Cell Development* , 2010, The Journal of Biological Chemistry.

[105]  A. Ashworth,et al.  An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers , 2010, Breast Cancer Research and Treatment.

[106]  P. Baumann,et al.  Telomerase RNA biogenesis involves sequential binding by Sm and Lsm complexes , 2012, Nature.

[107]  C. Milcarek,et al.  Expression of the thyroid hormone receptor gene, erbAalpha, in B lymphocytes: alternative mRNA processing is independent of differentiation but correlates with antisense RNA levels. , 1997, Nucleic acids research.

[108]  Efthimios Motakis,et al.  Complex sense-antisense architecture of TNFAIP1/POLDIP2 on 17q11.2 represents a novel transcriptional structural-functional gene module involved in breast cancer progression , 2010, BMC Genomics.

[109]  Daniel Birnbaum,et al.  A gene expression signature identifies two prognostic subgroups of basal breast cancer , 2011, Breast Cancer Research and Treatment.

[110]  Xu Li,et al.  Immunoscreening of urinary bladder cancer cDNA library and identification of potential tumor antigen , 2009, World Journal of Urology.

[111]  M. Kurosumi,et al.  The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways , 2009, Nature Cell Biology.

[112]  Zhiyuan Shen,et al.  BCCIP as a prognostic marker for radiotherapy of laryngeal cancer. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[113]  S. Batalov,et al.  Antisense Transcription in the Mammalian Transcriptome , 2005, Science.

[114]  C. Ng,et al.  Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. , 2009, The Journal of clinical endocrinology and metabolism.

[115]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[116]  Kerstin B. Meyer,et al.  Master regulators of FGFR2 signalling and breast cancer risk , 2013, Nature Communications.

[117]  L. Lipovich,et al.  Sense-antisense gene pairs: sequence, transcription, and structure are not conserved between human and mouse , 2013, Front. Genet..

[118]  M. Faghihi Regulation of gene expression by non-protein-coding RNAs , 2009 .

[119]  Heli Nevanlinna,et al.  A genomic map of a 6-Mb region at 13q21-q22 implicated in cancer development: identification and characterization of candidate genes , 2002, Human Genetics.

[120]  K. Nephew,et al.  CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha. , 2005, Molecular endocrinology.

[121]  P. Rudnai,et al.  SHMT1 1420 and MTHFR 677 variants are associated with rectal but not colon cancer , 2010, BMC Cancer.

[122]  P. Potter,et al.  The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. , 2013, Drug discovery today.

[123]  Audrey Kauffmann,et al.  Bioinformatics Applications Note Arrayqualitymetrics—a Bioconductor Package for Quality Assessment of Microarray Data , 2022 .

[124]  R. Greil,et al.  A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[125]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[126]  Renee Rubio,et al.  Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue , 2009, Breast Cancer Research and Treatment.

[127]  A. Børresen-Dale,et al.  Identification of fusion genes in breast cancer by paired-end RNA-sequencing , 2011, Genome Biology.

[128]  A. Nekrutenko,et al.  Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences , 2010, Genome Biology.

[129]  T. Yokota,et al.  GABPα regulates Oct-3/4 expression in mouse embryonic stem cells , 2007 .

[130]  T. Morgan,et al.  Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of β-secretase , 2008, Nature Medicine.

[131]  Hailun Wang,et al.  The PDZ protein TIP-1 facilitates cell migration and pulmonary metastasis of human invasive breast cancer cells in athymic mice. , 2012, Biochemical and biophysical research communications.

[132]  Gavin R. Oliver,et al.  Identification of differentially expressed sense and antisense transcript pairs in breast epithelial tissues , 2009, BMC Genomics.

[133]  Yun Cui,et al.  Bidirectional regulation between WDR83 and its natural antisense transcript DHPS in gastric cancer , 2012, Cell Research.

[134]  Roland Somogyi,et al.  Prediction of Graft-Versus-Host Disease in Humans by Donor Gene-Expression Profiling , 2007, PLoS medicine.

[135]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[136]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[137]  R. W. Williams,et al.  Antisense transcription: A critical look in both directions , 2008, Cellular and Molecular Life Sciences.